v3.26.3
STOCKHOLDERS' EQUITY (Tables)
 9 Months Ended
Sep. 30, 2026
Stockholders' Equity Note [Abstract]  
Schedule of Compensation Cost on Net Earnings
The Company’s results for the three and nine months ended September 30, 2026 and 2025 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings:

Increase/(Decrease) for theIncrease/(Decrease) for the
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Cost of sales$555 $382 $1,733 $1,356 
Operating expenses4,484 4,268 14,583 12,942 
Net earnings(3,910)(3,626)(12,610)(11,131)
Schedule of Assumptions Used in the Valuation of Option Awards For the nine months ended September 30, 2026, the fair value of each option grant was estimated on the date of the grant using the following weighted average assumptions:
Nine Months Ended September 30,
20262025
Dividend yields0.5 %0.6 %
Expected volatilities23.5 %26.0 %
Risk-free interest rates3.8 %4.5 %
Expected lives5.2 years5.2 years
A Monte-Carlo simulation has been used to estimate the fair value using the following assumptions:
Nine Months Ended September 30,
20262025
Dividend yields— %— %
Expected volatilities22.8 %25.5 %
Risk-free interest rates3.5 %4.3 %
Initial TSR's16.0 %-8.8 %
Schedule of Stock Option Activity
Option activity for the nine months ended September 30, 2026 and 2025 is summarized below:
For the Nine Months Ended September 30, 2026Shares (000s)Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding as of December 31, 2025900 $120.48 $29,888 5.2
Granted71 178.68 
Exercised(113)102.69 
Forfeited(1)143.43 
Canceled(2)139.31 
Outstanding as of September 30, 2026855 $127.57 $32,936 5.1
Exercisable as of September 30, 2026639 $116.86 $30,721 4.2
For the Nine Months Ended September 30, 2025Shares (000s)Weighted
Average
Exercise
Price		Aggregate
Intrinsic
Value		Weighted
Average
Remaining
Contractual
Term
Outstanding as of December 31, 2024962 $114.81 $46,346 5.8
Granted51 159.18 
Exercised(76)90.46 
Forfeited(3)142.33 
Canceled(1)139.81 
Outstanding as of September 30, 2025933 $119.11 $29,374 5.4
Exercisable as of September 30, 2025661 $108.04 $27,784 4.3
Schedule of Other Information Pertaining to Stock Option Activity
Other information pertaining to option activity during the three and nine months ended September 30, 2026 and 2025 is as follows:

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Weighted-average fair value of options granted$— $— $48.90 $48.86 
Total intrinsic value of stock options exercised ($000s)$2,491 $621 $8,058 $5,380 
Schedule of Non-vested Restricted Stock Activity
Non-vested restricted stock activity for the nine months ended September 30, 2026 and 2025 is summarized below:
Nine Months Ended September 30,
20262025
Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance as of December 31147 $150.15 122 $141.62 
Granted66 177.16 65 158.89 
Vested(52)145.16 (34)137.78 
Forfeited(5)156.26 (3)148.11 
Non-vested balance as of September 30156 $163.10 150 $149.84 
Schedule of Non-vested Performance Share Activity
Non-vested performance share activity for the nine months ended September 30, 2026 and 2025 is summarized below:

Nine Months Ended September 30,
20262025
Shares (000s)Weighted
Average Grant
Date Fair
Value		Shares (000s)Weighted
Average Grant
Date Fair
Value
Non-vested balance as of December 3181 $160.14 79 $150.73 
Granted50 173.60 50 147.96
Vested(35)148.64 (44)130.29
Forfeited— — (4)152.69
Non-vested balance as of September 3096 $171.52 81 $160.14